糖尿病视网膜病变:一个药理学考虑
Saket Y Maheshwari1, Sunil Kumar1, Arya Harshyt Sinha2
1Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Cureus
|November 13, 2023
概括
糖尿病视网膜病变 (DR),糖尿病的眼睛并发症,损害视网膜血管,可能导致失明. 抗血管内皮生长因子 (anti-VEGF) 治疗可以改善视力,副作用较少.
科学领域:
- 眼科医生 眼科 眼科
- 内分泌学 在内分泌学.
- 血管生物学 血管生物学
背景情况:
- 糖尿病 (DM) 是一个全球性的健康问题,在印度由高脂肪饮食加剧.
- 糖尿病视网膜病变 (DR) 是DM的严重并发症,由于高血糖症导致视网膜血管损伤.
- DR是导致失明的主要原因,其特点是小血管的病变以及视力模糊和色彩扭曲等症状.
研究的目的:
- 审查目前对糖尿病视网膜病变 (DR) 的理解和治疗.
- 突出DM和饮食对DR患病率的影响.
- 讨论抗血管内皮生长因子 (anti-VEGF) 治疗对治疗DR的疗效.
主要方法:
- 关于糖尿病视网膜病变的当前医学文献的综述.
- 分析现有的治疗方式,包括静脉内注射,激光光凝血和玻璃体手术.
- 专注于抗VEGF治疗的机制和应用.
主要成果:
- DR对视力构成重大威胁,视网膜微血管中的病变作为诊断基础.
- 目前的治疗方法旨在预防微血管并发症.
- 内抗VEGF疗法被认为是光学改善的关键治疗方法,副作用减少.
结论:
- 糖尿病视网膜病变是导致失明的主要原因,与糖尿病和饮食有关.
- 有效的管理策略对于预防视力丧失至关重要.
- 抗VEGF疗法在治疗糖尿病视网膜病变方面取得了重大进展.
相关概念视频
Diabetes: Management and Pharmacotherapy
290
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
290
Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Open Angle Glaucoma: Treatment
459
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
459
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Dipeptidyl Peptidase 4 Inhibitors
191
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
191
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K


